

**Figure 1.** Percent biomethylation of fluorinated olefinic fatty acids as a function of double bond position. The cyclopropyl product was identified in each case by comparison of its GC capillary retention time and MS (obtained by GC/MS) with authentic synthetic standards as previously described.<sup>5</sup>


methylating agent as shown in Figure 2.<sup>7</sup> Thus if the carbocation is generated at carbon 12 during methylation of vaccenic acid, then the carbocation must be formed at carbon 9 during methylation of oleic acid. Alternatively, if the carbocation is generated at carbon 11 during methylation of vaccenic acid, then it must be formed at carbon 10 during methylation of oleic acid. At this time we cannot distinguish between these two alternatives since we do not know precisely at what point(s) in the catalytic cycle the fluorine substituent effect is acting. The situation is complicated by the fact that we and others have produced evidence that the deprotonation step may be reversible.<sup>8,9</sup>

Our probe for the regiochemistry of carbocation formation has borne an important stereochemical consequence: namely that the absolute configurations of the cyclopropyl products derived from our fluorinated *cis*-vaccenates and oleates should turn out to be opposite in sense. We are currently preparing these fluorinated compounds in enantiomerically pure form in order to address this intriguing question. An important clue has already been obtained in collaboration with D. Arigoni and co-

(7) We wish to thank Professor D. Arigoni (ETH, Zürich) for helpful discussions on this point.

(8) Buist, P. H.; Maclean D. B. *Can. J. Chem.* 1982, 60, 371.

(9) Arigoni, D. *Chimia* 1987, 41, 9.



**Figure 2.** Relationship between the possible carbocationic intermediates derived from methylation of *cis*-9-octadecenoic acid and *cis*-11-octadecenoic acid.

workers who have determined that the absolute configuration of the cyclopropyl product produced by *L. plantarum* from 1 is 11*R*,12*S*, while the absolute configuration of the cyclopropyl product biosynthesized from 2 by the same bacterium is 9*S*,10*R*.<sup>10</sup> These findings rule out any mode of binding in which the same olefinic face of the two positional isomers is engaged.

In conclusion, we would like to point out that what began as a mechanistic study has serendipitously led us to raise an entirely unexpected issue: namely can a single enzyme or enzymic active site handle both positional isomers or are two isozymes involved? We anticipate being able to solve this problem using appropriate competition experiments with our fluorinated substrates. Should it turn out that a single active site is involved, important questions of fatty acid conformation will have been raised.

**Acknowledgment.** The financial support of NSERC and Carleton University is gratefully acknowledged. Gabe Leger and Judy Findlay were of invaluable assistance. We wish to thank Professor D. Arigoni (ETH, Zürich) for catalytic discussions.

(10) Manuscript in preparation.

## Enantioselective Route to $\gamma$ -Butyrolactones: Chiral Auxiliary Mediated Amide Alkylation and Iodolactonization

Samir Najdi, Daniel Reichlin, and Mark J. Kurth\*,<sup>1</sup>

Department of Chemistry, University of California, Davis, California 95616

Received October 1, 1990



**Summary:** A number of chiral,  $\gamma,\delta$ -unsaturated amides (1 and 2) have been prepared and their subsequent alkylation and iodolactonization to  $\gamma$ -butyrolactones (3) investigated.

(1) Recipient of an Alfred P. Sloan Research Fellowship, 1987-1991, and an NIH Research Career Development Award (ES00182), 1989-1994.

Earlier work in our laboratories has established that resident stereochemistry can profoundly influence the course of electrophilic cyclization reactions. For example, *d,l*-3,5-dimethylhepta-1,6-diene-4-carboxylic acid cyclizes<sup>2</sup>

















(2) Kurth, M. J.; Brown, E. G. *J. Am. Chem. Soc.* 1987, 109, 6844.

**Table I.  $\alpha$ -Alkylation of (*S*)-(+)-2-Pyrrolidinemethanol and (2*R*,6*R*)-(+)-2,6-Bis((benzyloxy)methyl)piperidine Derived Amides**

AUX-C(O)CH <sub>2</sub> R	R'X		
R = CH <sub>3</sub>	CH <sub>2</sub> =CHCH <sub>2</sub> Br	81:19 (4)	94:6 (9)
R = CH <sub>2</sub> CH=CH <sub>2</sub>	CH <sub>3</sub> I	73:27 (5)	>99:<1 (10)
R = CH <sub>2</sub> CH=CH <sub>2</sub>	CH <sub>2</sub> =C(CH <sub>3</sub> )CH <sub>2</sub> Cl	75:25 (6)	>99:<1 (11)
R = CH <sub>2</sub> C(CH <sub>3</sub> )=CH <sub>2</sub>	CH <sub>2</sub> =CHCH <sub>2</sub> Br	75:25 (7)	99:1 (12)
R = ( <i>E</i> )-CH <sub>2</sub> CH=CHCH <sub>3</sub>	CH <sub>2</sub> =CHCH <sub>2</sub> Br	82:18 (8)	95:5 (13)
R = CH <sub>2</sub> CH=CH <sub>2</sub>	( <i>E</i> )-CH <sub>3</sub> CH=CHCH <sub>2</sub> Br	-	(14) <sup>d</sup>

<sup>a</sup>The major product in each alkylation is the diastereomer depicted with the minor product being epimeric at C $\alpha$ . The number in parentheses is the compound number. <sup>b</sup>Diastereomer product ratios were determined by integration of diastereomeric signals in the 300-MHz <sup>1</sup>H NMR. <sup>c</sup>Diastereomer product ratios were determined by analytical HPLC (25 cm SiO<sub>2</sub> column, hexane-EtOAc 95:5, 1 mL/min). <sup>d</sup>A complex, inseparable mixture of S<sub>N</sub>2 and S<sub>N</sub>2' alkylation products was obtained.


**Table II. Enantioselective Iodolactonization of (*S*)-(+)-2-Pyrrolidinemethanol and (2*R*,6*R*)-(+)-2,6-Bis((benzyloxy)methyl)piperidine Derived Amides**

entry	cyclization method <sup>a</sup>	amide				
i	A	4	75	17	6	2
ii	A	5	24	68	3	5
iii	B	9	79	11	8	2
iv	B	10	11	83	1	5
						
v	A	6	49	4	27	20
vi	B	11	49	1	23	27
						
vii	C	7	40	2	36	22
viii	B	12	4	0	38	58
						
ix	A	8	78	8	12	2
x	C	13	8	0	10	82

<sup>a</sup>Cyclization methods: A = 3 equiv of I<sub>2</sub>, DME-H<sub>2</sub>O, 1:1, room temperature, ≈3 days, B = 3 equiv of I<sub>2</sub>, THF-H<sub>2</sub>O, 1:1, 0 °C, ≈3 days; C = 3 equiv of I<sub>2</sub>, THF-H<sub>2</sub>O, room temperature, ≈3 days.

with remarkable olefin and face selectivity, while the various diastereomers of 3-hydroxy-2-(2'-methylene-cyclohexan-1'-yl)butyric acid cyclize<sup>3</sup> with complete nucleophile (i.e., OH vs CO<sub>2</sub>R) and face selectivity. These observations, coupled with numerous reports of excellent diastereoselectivity in both the C-alkylation of chiral amides<sup>4</sup> and the electrophilic cyclization of  $\alpha$ -branched  $\gamma,\delta$ -unsaturated *N,N*-dialkylamides,<sup>5</sup> led us to develop a versatile synthesis of chiral  $\gamma$ -butyrolactones by a three-step route consisting of N-acylation of chiral amines, C $\alpha$ -alkylation, and iodolactonization. Chiral auxiliaries employed in the this study

were (*S*)-(+)-2-pyrrolidinemethanol<sup>6</sup> as in amide 1 and (2*R*,6*R*)-(+)-2,6-bis((benzyloxy)methyl)piperidine [(+)-BBMP]<sup>6b</sup> as in amide 2. As evidenced by the much greater diastereoselectivity obtained with amide 2 ( $\rightarrow$  3 vs 1  $\rightarrow$  3), the "C<sub>2</sub> symmetry axis"<sup>7</sup> of (+)-BBMP plays a pivotal role, both in the alkylation and iodolactonization steps.



Our starting chiral amides (i.e., AUX-C(O)CH<sub>2</sub>R in Table I) were prepared from the chiral amine and the

(3) Kurth, M. J.; Beard, R. L.; Macmillan, J. G.; Olmstead, M. *J. Am. Chem. Soc.* **1989**, *111*, 3712.

(4) (a) Sonnet, P. E.; Heath, R. R. *J. Org. Chem.* **1980**, *45*, 3137. (b) Evans, D. A.; Takacs, J. M. *Tetrahedron Lett.* **1980**, *21*, 4233. (c) Mori, K.; Ito, T. *Tetrahedron* **1983**, *39*, 2303. (d) Kawanami, Y.; Ito, Y.; Kitagawa, T.; Taniguchi, Y.; Katsuki, T.; Yamaguchi, M. *Tetrahedron Lett.* **1984**, *25*, 857. (e) Ito, Y.; Katsuki, T.; Yamaguchi, M. *Ibid.* **1984**, *25*, 6015. (f) Enomoto, M.; Ito, Y.; Katsuki, T.; Yamaguchi, M. *Ibid.* **1985**, *26*, 1343. (g) Schultz, A.; Sundararaman, P.; Macielag, M.; Lavieri, F. P.; Welch, M. *Ibid.* **1985**, *26*, 4575. (h) Ito, Y.; Katsuki, T.; Yamaguchi, M. *Ibid.* **1985**, *26*, 4643. (i) Hanamoto, T.; Katsuki, T.; Yamaguchi, M. *Ibid.* **1986**, *27*, 2463. (j) Uchikawa, M.; Hanamoto, T.; Katsuki, T.; Yamaguchi, M. *Ibid.* **1986**, *27*, 4577. (k) Evans, D. A.; Dow, R. L.; Shih, T. L.; Takacs, J. M.; Zahler, R. *J. Am. Chem. Soc.* **1990**, *112*, 5290.

(5) (a) Tamaru, Y.; Mizutani, M.; Furukawa, Y.; Kawamura, S.; Yoshida, Z.; Yanagi, K.; Minobe, M. *J. Am. Chem. Soc.* **1984**, *106*, 1079. (b) Hart, D. J.; Huang, H. C.; Krishnamurthy, R.; Schwartz, T. *Ibid.* **1989**, *111*, 7507. (c) Fuji, K.; Node, M.; Naniwa, Y.; Kawabata, T. *Tetrahedron Lett.* **1990**, *31*, 3175.

(6) (a) (*S*)-(+)-2-Pyrrolidinemethanol ( $\approx$ 100% ee) is commercially available from the Aldrich Chemical Company, Inc. [18,651-1]. (b) (2*R*,6*R*)-(+)-2,6-Bis((benzyloxy)methyl)piperidine ( $\approx$ 76% ee) was prepared from (*S*)-(+)-2-((benzyloxy)methyl)oxirane ( $\approx$ 76% ee; Aldrich Chemical Company, Inc. [36-353-7]). See: Najdi, S.; Kurth, M. *J. Tetrahedron Lett.* **1990**, *31*, 3279. Consequently, the major iodolactone product in entries iii/iv/vi/viii/x of Table II was obtained in  $\approx$ 75% ee.

(7) (a) A strict application of the C<sub>2</sub> symmetry element does not apply in the ground-state arrangement of (2*R*,6*R*)-(+)-2,6-bis((benzyloxy)methyl)piperidine. However, this substrate possess functional C<sub>2</sub> symmetry<sup>7b</sup> since the nitrogen atom, which lies on the pseudo-C<sub>2</sub> axis, is chirotopic but nonstereogenic. (b) Whitesell, J. K. *Chem. Rev.* **1989**, *89*, 1581-90.


corresponding anhydride (or the trimethylacetic-mixed anhydride) by treatment with triethylamine (1.2 equiv) and 4-(dimethylamino)pyridine (0.05 equiv) at room temperature in dichloromethane. Subsequent enolate formation (THF,  $-78^{\circ}\text{C}$ , 2.1 equiv of LDA with amide 1 or 1.1 equiv of LDA with amide 2) and alkylation produced the  $C_{\alpha}$ -alkylated amides in Table I. As a point of clarification, these alkylation conditions are optimized for the piperidine series ( $\geq 94\%$  ds and 60–93% yield) but not the pyrrolidine series,<sup>8</sup> and the relative stereochemistry at  $C_{\alpha}$  in amides 4–14 was assigned by analogy with previous examples of chiral amide alkylations.<sup>6</sup>

Iodolactonization of 4–13 was anticipated to (i) liberate the chiral auxiliary for recovery and recycle, (ii) exploit amide resident stereochemistry as the critical control element in establishing new stereogenic center(s) as the olefinic carbons undergo  $sp^2 \rightarrow sp^3$  rehybridization, and (iii), in the case of dienamides 7/8/12/13, differentiate and selectively cyclize one of the two olefinic moieties. Furthermore, entries i–iv in Table II illustrate three unique features of this iodolactonization reaction. First, these *N*-pyrrolidino (4 and 5) and *N*-piperidino (9 and 10) 2-methylpent-4-enamides are moderately more *trans* selective than Yoshida's *N,N*-dimethyl-2-methylpent-4-enamide ( $\geq 9:1$  *trans*-15:*cis*-16). Second, since the amide  $C_{\alpha}$ -alkylation reaction proceeds with moderate to excellent diastereoselectivity on a nonracemic substrate (see Table I), the *trans*-iodolactone is formed enantioselectively. Third, either antipode of the *trans*-iodolactone can be prepared by simply controlling the  $C_{\alpha}$  relative stereochemistry in the amide alkylation step [i.e., 4/9  $\rightarrow$  (*R,S*)-15 and 5/10  $\rightarrow$  (*S,R*)-15]. The degree of overall enantioselectivity in the preparation of 15–24 is a consequence of both the degree of diastereoselectivity in the amide  $C_{\alpha}$ -alkylation step<sup>9</sup> and the optical purity of the starting chiral auxiliary.<sup>6b</sup>

In parallel with Yoshida's *N,N*-dimethylamide,<sup>7a</sup> amides 4–13 undergo *trans*-selective iodolactonization because A(1,3) strain<sup>10</sup> disfavors the *pro-cis* transition state (cf., *pro-cis*-4 or *pro-cis*-9), forcing the  $\alpha$ -alkyl substituent to adopt a quasi-axial orientation as in *pro-trans*-4 and *pro-trans*-9. Thus, while the pyrrolidino and piperidino chiral auxiliaries differentiate the *re* and *si* faces of the amide enolate in the  $C_{\alpha}$ -alkylation step, they afford no advantage over the *N,N*-dimethyl moiety in the iodolactonization step for substrates with only one site of  $\gamma,\delta$ -unsaturation. Entries viii and x (Table II) demonstrate that the (+)-BBMP auxiliary profoundly influences the iodolactonization of dienamides!


The critical role played by the chiral auxiliary in the heterocyclization reaction is most apparent in iodolactonizations of (*E*)-1,6-octadiene-4-carboxylic acid derivatives. Kinetic iodolactonization of the lithium carboxylate (THF,  $-78^{\circ}\text{C}$ ) gives a 15:27:22:36 (42:58 allyl-crotyl selectivity) mixture of ( $\pm$ )-lactones 21, 22, 23, and 24, respectively, whereas the corresponding pyrrolidine amide gives the same lactones as a 61:4:30:5 (65:35, allyl-*N*-crotyl selectivity) mixture. The (*S*)-(+)-2-pyrrolidinemethanol derivative (amide 8, Table II/entry

ix) is marginally more allyl selective (86:14; 78:8:12:2 mixture of the four lactones). This progression from crotyl to allyl selectivity reflects the amide's kinetic preference for the least hindered olefin, a bias which intensifies as the amide becomes more hindered, and the dramatic switch from  $\approx 3:2$  *cis* selectivity with the acid to  $\approx 10:1$  *trans* selectivity with chiral amide 8 reflects the significance of A(1,3) strain.



Remarkably, the derivative 13 is crotyl selective (8:92, 8:0:10:82 mixture of the four lactones)! This changeover in olefin selectivity can be understood as follows. Olefin selectivity in the iodolactonization of 8 (*pro-crotyl*-8 vs *pro-allyl*-8) reflects a kinetic preference of the amide moiety for the least hindered olefin; the stereogenic center in the chiral amine has little additional influence on the reaction. In contrast, 13 experiences significant destabilization of the *pro-allyl* transition state by a benzyloxy-methyl-crotyl interaction<sup>11</sup> and the *pro-crotyl* transition state is preferred over the least hindered olefin (i.e., 8  $\rightarrow$  *trans*-21)! The significance of this (benzyloxy)methyl interaction is further underscored with amides 6/7 and 11/12 (Table II entries vi and viii). While amides 6, 7 (Table II entries v and vii), and 11 (entry vi) give approximately equal allyl and methallyl cyclization, (+)-BBMP amide 12 (entry viii) is 96:4 methallyl selective because both conformation (i.e., a destabilizing benzyloxymethyl-methallyl interaction in its *pro-allyl* transition state) and electronics<sup>12</sup>

(11) (a) This 92:8 crotyl selectivity reflects destabilization (by a benzyloxy-crotyl interaction) of the *pro-allyl*-13 transition state relative to the *pro-crotyl*-13 transition state. Indeed, MM2 modeling<sup>11b</sup> of simplified analog I indicates that the  $C_2$ -methyl/ $C_{\alpha}$ -methyl "eclipsed" conformation Ib (i.e., a ground-state analogue of *pro-allyl*-13) is destabilized by 0.65 kcal/mol relative to the  $C_2$ -methyl/ $C_{\alpha}$ -hydrogen "eclipsed" conformation Ia (i.e., a ground-state analogue of *pro-crotyl*-13).



(b) MM2 77 Allinger-QCEP395 and MMP1 Pi Allinger-QCEP318 which includes model parameters by Still and atom and trial constants by K. E. Gilbert and J. J. Gajewski, Indiana University.

(8) For a detailed experimental procedure and optimal alkylation conditions for alkylation of (*S*)-(+)-2-pyrrolidinemethanol derived amides, see ref 4k.

(9) For iodolactones 15 and 16, enantiomeric excesses were determined by HPLC ( $\text{SiO}_2$ /hexane-EtOAc, 19:1) separation of the *cis* and *trans* mixture and then enantiomer resolution by capillary GC [ $\beta$ -cyclodextrin on OV-1701 (30-m) column,  $100^{\circ}\text{C}$  isothermal,  $\text{H}_2$  at 6 psi:  $R_f$  (*R,S*)-15 = 157.8 min,  $R_f$  (*S,R*)-15 = 160.2 min].

(10) (a) See ref 7a. (b) Johnson, F. *Chem. Rev.* 1968, 68, 375. (c) Overman, L. E.; Yokomatsu, T. *J. Org. Chem.* 1980, 45, 5229. (d) Wilson, S. R.; Misra, R. N. *Ibid.* 1980, 45, 5079.

